
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is attractive fundamentally because its cloud-based, pay-per-analysis SaaS model converts increasingly complex multimodal genomic data into recurring high-margin revenue without owning lab infrastructure, while adjusted gross margin reached 74.2% in 2025 and 75.4% in 1Q26. Its moat is reinforced by a compounding global network of roughly 1,000 hospitals and laboratories across 75 countries, more than 2.5 million genomic profiles, and strong retention metrics including 117% net dollar retention and below-1% annualized churn. The bullish case is further supported by 2025 revenue of $77.3M, 2026 guidance of $92M–$96M, large U.S. health-system wins, and improving BioPharma momentum through partnerships such as AstraZeneca, Johnson & Johnson, and Myriad Genetics.
Bears say
Sophia Genetics is challenged by weak fundamental profitability and uneven monetization, as 2024 revenue growth was just 4% despite 11% volume growth, implying a 6-7% decline in revenue per analysis amid biopharma headwinds. Its future depends heavily on scaling the SOPHiA DDM Platform and newer liquid-biopsy products, but with only about 100 MSK-ACCESS and MSK-IMPACT customers combined and roughly half of liquid-biopsy accounts still in implementation as of 1Q26, commercialization remains unproven. Competitive, cybersecurity, legal, and dilution risks also weigh on the outlook, especially because the company is not yet profitable and may need additional capital that could dilute shareholders.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Sophia Genetics SA (SOPH) Forecast
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares